Janus Henderson Group PLC Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Janus Henderson Group PLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 460,419 shares of the biotechnology company's stock after acquiring an additional 50,409 shares during the period. Janus Henderson Group PLC owned approximately 1.03% of United Therapeutics worth $164,978,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. B. Riley Wealth Advisors Inc. bought a new stake in shares of United Therapeutics during the 1st quarter worth $219,000. Cetera Advisors LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at $475,000. GAMMA Investing LLC grew its holdings in shares of United Therapeutics by 84.8% during the 2nd quarter. GAMMA Investing LLC now owns 390 shares of the biotechnology company's stock valued at $124,000 after purchasing an additional 179 shares during the last quarter. Park Avenue Securities LLC raised its position in United Therapeutics by 30.4% in the 2nd quarter. Park Avenue Securities LLC now owns 2,037 shares of the biotechnology company's stock worth $649,000 after purchasing an additional 475 shares during the period. Finally, CWM LLC lifted its stake in United Therapeutics by 11.0% in the second quarter. CWM LLC now owns 1,923 shares of the biotechnology company's stock worth $613,000 after purchasing an additional 191 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research report on Friday, November 1st. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Finally, LADENBURG THALM/SH SH increased their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of the company's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 12.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 119,442 shares of company stock valued at $44,577,770 in the last ninety days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

UTHR stock traded down $0.03 during midday trading on Thursday, hitting $374.37. The stock had a trading volume of 241,661 shares, compared to its average volume of 452,964. The firm has a market cap of $16.72 billion, a price-to-earnings ratio of 16.44, a price-to-earnings-growth ratio of 1.07 and a beta of 0.54. The business has a 50-day moving average of $368.58 and a two-hundred day moving average of $337.70. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue was up 22.9% on a year-over-year basis. During the same period last year, the company posted $5.38 EPS. Research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.